title: Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies.
abstract: One hundred and sixty eight adult patients with B-cell non-Hodgkin's lymphoma (NHL) and other hematologic malignancies who underwent autologous or allogeneic bone marrow transplantation (BMT) were investigated for the subsequent development of hemolytic-uremic syndrome (HUS). All patients were conditioned with cyclophosphamide and total body irradiation. When examined at 3-month intervals for the first year post-BMT, all patients had uniform measurements of hematocrit (Hct) and serum creatinine. Sixteen patients who initially exhibited Hct and creatinine values that were normal range for the BMT populations developed a sudden decrease in Hct and increase in creatinine between 3 and 11 months post-BMT and fulfilled the clinical and laboratory criteria for HUS. None of these patients had known active cytomegalovirus infection, graft-versus-host disease, or cyclosporine administration. The degree of decrease in Hct and creatinine elevation ranged from solely laboratory abnormalities to a clinically significant syndrome. Twelve of the 16 patients developed acute clinical complications of congestive heart failure, hypertension (HTN), or peripheral edema. Twelve patients required red blood cell support, whereas only four patients required platelet transfusions. Both hemolytic anemia and thrombocytopenia have resolved in virtually all cases. At a mean follow up of 18 months postdiagnosis, creatinine elevations have persisted along with HTN. All patients have survived without life-threatening long-term sequelae. With the increasing use of BMT as a curative modality for patients with hematologic malignancies, it becomes important to prospectively monitor patients for the development of HUS and its potential long-term impact on renal function.
authors.affiliation: Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115.
authors.forename: S N
authors.initials: SN
authors.lastname: Rabinowe
authors.forename: R J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: N J
authors.initials: NJ
authors.lastname: Tarbell
authors.forename: D
authors.initials: D
authors.lastname: Neuberg
authors.forename: A S
authors.initials: AS
authors.lastname: Freedman
authors.forename: J
authors.initials: J
authors.lastname: Seifter
authors.forename: K W
authors.initials: KW
authors.lastname: Blake
authors.forename: J G
authors.initials: JG
authors.lastname: Gribben
authors.forename: K C
authors.initials: KC
authors.lastname: Anderson
authors.forename: T
authors.initials: T
authors.lastname: Takvorian
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000502:physiology; D003520:Cyclophosphamide / Q000627:therapeutic use; D006400:Hematocrit; D006463:Hemolytic-Uremic Syndrome / Q000209:etiology*; D006801:Humans; D007677:Kidney Function Tests; D007938:Leukemia / Q000601:surgery*; D008228:Lymphoma, Non-Hodgkin / Q000601:surgery*; D008875:Middle Aged; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014916:Whole-Body Irradiation
chemical_list: D003520:Cyclophosphamide